CGD Policy Blogs
In a recent blog, I bemoaned the fact that donors were unable to secure the estimated $100 million needed to test and confirm the HIV prevention success of the CAPRISA microbicide. The comments on that blog by scientific writers Jon Cohen and Roger Tatoud point out that other trials of microbicide gels are in the works and that one in particular, the so-called VOICE trial, is both close to comple
Celia Dugger must have known she would get a reaction. She called from South Africa last week with the surprising news that a donor meeting in South Africa had failed to come up with the $100 million necessary to complete the preparatory research on microbicides as an HIV prevention tool for women. Luckily for me, she considered my spontaneous reaction to be unprintable and persisted until she got a more coherent quote from me, a quote that appears in her succinct and informative New York Times article
A Refreshingly Open Debate on the Value of Universal Access to AIDS Treatment for U.S. Foreign Policy
The Center for Strategic and International Studies (CSIS) hosted a debate last Friday with the provocative title “Resolved: That the US commitment to universal HIV/AIDS treatment is unsustainable and decreases US leverage in the nations’ foreign policy.” (Note: This resolution which you will hear debated is edgier and has more foreign policy content than the one you will see when you click on the above link.) Moderated by
The Wonkcast is taking a brief summer vacation. We've selected this show from our archives- it was originally posted on May 25, 2010.
Even as the cost of treating HIV/AIDS has fallen dramatically, the number of people newly infected has remained high. What can be done to reverse this trend and finally defeat this disease? This week on the Wonkcast, I’m joined by Mead Over, a senior fellow here at the Center for Global Development and perhaps the world’s leading expert on the economics of HIV/AIDS. He has recently published two major essays, which introduce the concept of the “AIDS transition”—the point in time where the number of people living with the disease begins to fall. He argues persuasively that to reach this point, international donors must greatly strengthen incentives for effective prevention.
The biggest news from the 2010 AIDS Conference was no doubt the encouraging results from the Centre for the AIDS Programme of Research in South Africa’s (CAPRISA) trial of a female microbicide gel to block the transmission of HIV.
Under the banner “Rights Here, Right Now,” the International AIDS Conference currently taking place in Vienna is committed to translating funding for human rights-based programming for HIV to address the stigma and discrimination that often impede an effective response. On Wednesday, Global Fund executive director Michel Kazatchkine and others participated in a session titled “The Global Fund: Proving Impact, Promoting Rights.” The majority of their discussion focused on how the Global Fund can better address t
Just as the 2000 AIDS conference in Durban, South Africa was a watershed for AIDS treatment, the AIDS conference taking place now in Vienna is a watershed for HIV prevention. For the first time since our naïve optimism of the 1990s, we have some of the tools to effectively reduce the annual incidence rate of HIV (i.e.
Not as large or energizing as previous AIDS conferences, the Vienna 2010 jamboree officially kicked off on Sunday night at the Messe Wien Center. Soothing classical music wafted through the auditorium, creating a somewhat surreal setting for a conference that will be characterized by frustration and bitterness about the world's flagging funding commitments to combating AIDS. Protestors gathered their banners and posters and marched through the auditorium shouting: "Broken Promises Kill. No Retreat.
Here in Vienna, at the crossroads of Europe, 20,000 people from 185 countries have gathered for the 18th International AIDS Conference. The Austrian physician who chairs the conference, Dr.